CIRBP

Across TCGA pan-cancer cohorts, CIRBP Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CIRBP data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CIRBP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CIRBP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, KIRC, and COAD are the cancer types where CIRBP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.198	0.872	.003	18	view →
KIRC	OS	Median	All	0.152	0.874	<.001	12	view →
COAD	OS	Median	All	0.546	0.870	.018	4	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →
UCEC	OS	Median	All	1.000	0.866	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CIRBP–ESCA (OS)

Open the ESCA breakdown →